CHARM Therapeutics Secures $80M Series B Financing to Advance Next-Generation Menin Inhibitor into Clinical Development

September 2,London, CHARM Therapeutics Announces Oversubscribed Series B Financing, Raising $80 Million to Advance ItsNext GenerationmeninInhibitor'sClinical Development. The financing was supported by a strong consortium of existing and new global investors, reflecting the confidence in the company's ability to overcomemeninA Breakthrough Approach to Overcoming Inhibitor Resistance, a Key Limitation of First-Generation Therapies.

This round of financing was co-led by New Enterprise Associates (NEA) and SR One, with participation from existing investors OrbiMed, F-Prime, Khosla Ventures, and NVIDIA.

CHARM Therapeutics, founded by Laksh Aithani and David Baker, is pioneering the next generation of precision oncology treatments through its proprietary AI-driven drug discovery platform.CHARM Therapeutics has raised over 150 million US dollars from leading international investors, including New Enterprise Associates (NEA), SR One, OrbiMed, F-Prime, Khosla Ventures and NVIDIA. The company is advancing its leadingmeninInhibitor Candidate Advances to Clinical Development by Early 2026.

The Next Generation of CHARMmeninInhibitor

Acute Myeloid Leukemia (AML) is a rapidly progressing and highly aggressive cancer, with many patients experiencing poor prognoses. Menin inhibitors have recently emerged as a clinically validated therapeutic class, functioning by restoring normal gene regulation and triggering differentiation or death in cancer cells. However, first-generation therapies are limited bymeninThe limitation of rapid emergence of protein resistance mutations, which can reduce efficacy and lead to recurrence and disease progression. Additionally, some first-generationmeninThe efficacy of inhibitors may be limited by safety risks, including QTc prolongation and poor drug properties, such as the potential for drug interactions and the need for high doses.

CHARM Therapeutics is developing a new generationmeninInhibitors, designed to overcome these limitations. CHARM Therapeutics utilizes its proprietary protein-ligand co-folding platform, DragonFold, to identify a development candidate that retains potency against all publicly described clinical resistance mutations and has demonstrated robust tumor regression in preclinical models. This molecule is expected to be effective at low human doses, without prolonging the QTc interval or inhibiting enzymes responsible for drug interactions.

Through high-quality molecule design supported by artificial intelligence, CHARM Therapeutics aims to unlock new possibilities for AML patients.meninThe full potential of inhibition, and provide a larger, more sustained therapeutic response.

Gary D. Glick, Ph.D., Executive Chairman of CHARM Therapeutics, stated:"Securing funding from such a high-quality consortium of investors is a testament to our ability to overcomemeninA powerful validation of methods for inhibitor resistance. Currently,menin"Inhibitors have shown promise in AML treatment but are fundamentally limited by the rapid emergence of resistance mutations that lead to treatment failure. Our next-generation inhibitor, discovered using our proprietary DragonFold AI platform, is specifically designed to overcome these resistance mutations and deliver the durable responses patients need. This program represents a significant opportunity to transform patient outcomes, and we look forward to initiating clinical development early next year."

Strategic Board Appointment

As CHARM advances its leading Menin inhibitor candidate into the clinic, the company has strengthened its board with the appointment of Dr. Briggs Morrison as a non-executive director. Briggs bringsmeninHas valuable expertise in inhibitor development and a deep understanding of the AML treatment landscape from his previous role as CEO of Syndax, the company that developed the first FDA-approvedmeninThe company of the inhibitor revumenib. In addition, Kim BlackwellDoctor of MedicineJoined the board as a non-executive director, contributing extensive oncology and clinical development expertise to the advancement of CHARM Therapeutics Inc.'s clinical programs.

Following the Series B financing, NEA partner Matthew McAviney, M.D., and SR One senior associate Mahesh Kudari, M.D., will also join the board as non-executive directors to support CHARM Therapeutics Inc. in the strategic execution of its clinical trials.

Matthew McAviney, M.D., Partner at New Enterprise Associates, stated:"We are delighted to be at CHARM Therapeutics with its highly promising next-generationmenin"Providing support as the inhibitor transitions to the clinic. The strength of the preclinical data and the clarity of the clinical development plan enable CHARM to make a meaningful impact for patients facing refractory cancers. We are proud to support CHARM in its next phase of growth."

Mahesh Kudari, M.D., Senior Associate at S.R.One Ltd., said:"CHARM Therapeutics utilizes its proprietary protein-ligand co-folding platform, DragonFold, to rapidly identify highly potent next-generation compounds active against drug-resistant mutations."menin"Inhibitor. We are delighted to support this project as it moves into the clinical trial phase and look forward to collaborating with the team."

Follow the official account below to explore the world with you!